ADC Therapeutics to Participate in Cowen's 42 nd Annual Health Care Conference

ADC Therapeutics to Participate in Cowen's

42nd Annual Health Care Conference

LAUSANNE, Switzerland, March 1, 2022 -

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation,

targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, announced today that Chris Martin,

DPhil, Chief Executive Officer, will participate in a fireside chat at Cowen's virtual 42nd Annual Health Care Conference

on Tuesday, March 8th at 2:10 p.m. EST.

A live webcast of the presentation will be available

via the Events & Presentations page in the Investors section of ADC Therapeutics' website, ir.adctherapeutics.com.

A replay of the webcast will be available for approximately 30 days.

About ADC Therapeutics

ADC Therapeutics (NYSE: ADCT) is a commercial-stage

biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The

Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies

ADC Therapeutics' CD19-directed ADC ZYNLONTA

(loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two

or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab tesirine) is being

evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced

solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.

ADC Therapeutics is based in Lausanne (Biop le),

Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/

and follow the Company on Twitter and LinkedIn.

ZYNLONTA is a registered trademark of ADC Therapeutics